For the quarter ending 2025-09-30, CLRB had $1,513,262 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,443,876 | -12,051,940 |
| Depreciation and amortization | 52,277 | 111,859 |
| Stock-based compensation expense | 567,788 | 1,128,128 |
| Change in operating lease right-of-use asset | 19,407 | 36,626 |
| Change in fair value of warrants | -294,276 | -161,598 |
| Prepaid expenses and other current assets | -509,170 | 614,914 |
| Lease liability | -21,580 | -40,494 |
| Accounts payable and accrued liabilities | -664,031 | -2,906,627 |
| Cash used in operating activities | -4,275,121 | -14,498,960 |
| Proceeds from exercise of warrants, net of issuance costs (note 2) | 0 | 2,251,380 |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs (note 2) | 5,788,380 | - |
| Issuance of common stock in connection with exercise of pre-funded warrants | 3 | - |
| Cash provided by financing activities | 5,788,383 | 2,251,380 |
| Net (decrease) increase in cash and cash equivalents | 1,513,262 | -12,247,580 |
| Cash and cash equivalents at beginning of period | 23,288,607 | - |
| Cash and cash equivalents at end of period | 12,554,289 | - |
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc. (CLRB)